After Wedbush and Needham gave Albireo Pharma (NASDAQ: ALBO) a Buy rating last month, the company received another Buy, this time from William Blair. Analyst Tim Lugo maintained a Buy rating on Albireo Pharma today. The company’s shares closed last Monday at $17.74.
According to TipRanks.com, Lugo is a 2-star analyst with an average return of 0.0% and a 35.1% success rate. Lugo covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Collegium Pharmaceutical, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Albireo Pharma is a Strong Buy with an average price target of $52.75, representing a 192.7% upside. In a report released yesterday, Wedbush also maintained a Buy rating on the stock with a $60.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $38.69 and a one-year low of $11.26. Currently, Albireo Pharma has an average volume of 117K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Albireo Pharma, Inc. is a pharmaceutical company, which engages in the development and commercialization of bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its product pipeline includes A4250, Elobixibat, and A3384. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.
